Oryzon Genomics - Public Comps and Valuation Multiples

Oryzon Genomics Overview

About Oryzon Genomics

Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.

Founded

2000

HQ

Employees

Website

oryzon.com

Sectors

Drug Development & Therapeutics
Genomics & Personalized Medicine
BioTech
DeepTech

Financials

Last FY Revenue n/a

LTM EBITDA -$5.1M

EV

$287M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Oryzon Genomics Financials

As of September 2025, Oryzon Genomics reported last 12-month EBITDA of -$5.1M.

In the same period, Oryzon Genomics achieved -$3.9M in LTM net income.

See Oryzon Genomics valuation multiples based on analyst estimates

Oryzon Genomics P&L

In the most recent fiscal year, Oryzon Genomics reported EBITDA of -$4.9M.

Oryzon Genomics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Oryzon Genomics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	n/a	XXX	n/a	XXX	XXX	XXX
Gross Profit	n/a	XXX	$8.2M	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	-$5.1M	XXX	-$4.9M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBIT	-$8.1M	XXX	-$5.1M	XXX	XXX	XXX
EBIT Margin	n/a	XXX	n/a	XXX	XXX	XXX
Net Profit	-$3.9M	XXX	-$4.2M	XXX	XXX	XXX
Net Margin	n/a	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	XXX	$6.4M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Oryzon Genomics including revenue, profitability, and margin analysis across different time periods. EBITDA for the last twelve months was -$5.1M.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$8.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$5.1M	Analyst estimates available to subscribers	-$4.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$8.1M	Analyst estimates available to subscribers	-$5.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$3.9M	Analyst estimates available to subscribers	-$4.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$6.4M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Oryzon Genomics

This financial data table provides comprehensive performance metrics for Oryzon Genomics, a company based in Spain. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

The company achieved -$5.1M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$3.9M.

Fiscal Year Performance

Fiscal year EBITDA was -$4.9M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Oryzon Genomics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Oryzon Genomics Stock Performance

Oryzon Genomics has current market cap of EUR 266M (or $307M), and EV of EUR 248M (or $287M).

Market Cap Evolution

Oryzon Genomics Stock Data

As of October 17, 2025, Oryzon Genomics's stock price is EUR 3 (or $4).

See Oryzon Genomics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$287M	$307M	XXX	XXX	XXX	XXX	$-0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Oryzon Genomics Valuation Multiples

Oryzon Genomics's trades at n/a EV/Revenue multiple, and -59.2x EV/EBITDA.

See valuation multiples for Oryzon Genomics and 15K+ public comps

Oryzon Genomics Financial Valuation Multiples

As of October 17, 2025, Oryzon Genomics has market cap of $307M and EV of $287M.

Equity research analysts estimate Oryzon Genomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Oryzon Genomics has a P/E ratio of -78.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$307M	XXX	$307M	XXX	XXX	XXX
EV (current)	$287M	XXX	$287M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	n/a	XXX	XXX	XXX
EV/EBITDA	-55.8x	XXX	-59.2x	XXX	XXX	XXX
EV/EBIT	-35.5x	XXX	-56.2x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-78.7x	XXX	-72.5x	XXX	XXX	XXX
EV/FCF	-37.8x	XXX	-18.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Oryzon Genomics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Oryzon Genomics Margins & Growth Rates

Oryzon Genomics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.3M for the same period.

Oryzon Genomics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Oryzon Genomics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Oryzon Genomics and other 15K+ public comps

Oryzon Genomics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	-250%	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial